All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your ALL Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma Hub

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2021-02-04T10:10:41.000Z

How can NK cells act as reliable predictors and be translated to diagnostics and treatment in ALL?

By Paola Frisone, Joshua Reid
Featured
Srividya Swaminathan
Feb 4, 2021
Share:

Bookmark this article

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the ALL Hub spoke to Srividya Swaminathan, The Department of Systems Biology at the Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. We asked, How can natural killer (NK) cells act as reliable predictors and be translated to diagnostics and treatment in ALL?

How can NK cells act as reliable predictors and be translated to diagnostics and treatment in ALL?

Swaminathan reports the results of a study evaluating the phenotypic and functional deficiencies in NK cells of high-risk patients with ALL. Results from this study show that activated NK signature predicts poor clinical prognosis in high-risk patients with ALL.


More about...
Allo-NKTASH 2020Cellular therapyHigh-risk

Related articles

Add bookmark

Novel concepts to target CD22 with CAR T-cell therapy for R/R B-ALL

Relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) is a difficult to treat disease with poor prognosis. Two anti-CD19 chimeric antigen receptor (CAR) T-cell...

Feb 25, 2021
Add bookmark

Novel concepts to target CD22 with CAR T-cell therapy for R/R B-ALL

Relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) is a difficult to treat disease with poor prognosis. Two...

Feb 25, 2021
Add bookmark

Young adult and pediatric ALL: Current induction regimens and prognostic factors

In a review published in Expert Review of Hematology, Saveria Capria and colleagues discuss the currently available induction treatments for children and adolescents...

Aug 28, 2020
Add bookmark

Young adult and pediatric ALL: Current induction regimens and prognostic factors

In a review published in Expert Review of Hematology, Saveria Capria and colleagues discuss the currently available...

Aug 28, 2020

Newsletter

Subscribe to get the best content related to ALL delivered to your inbox